RCT of anti-inflammatory agents for choroidal neovascularization in age-related macular degeneration
This randomised controlled trial evaluated whether infliximab, sirolimus, or daclizumab combined with standard AMD care would prevent new blood vessel growth in the eye compared to observation alone. The study enrolled participants aged 55+ with AMD and drusen >63 μm, with baseline vision between 20/20 and 20/400. Participants received one of three treatments or observation only, with evaluations at 6 months including retinal imaging, angiography, and blood tests.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 29, 2016 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 6 months
- Population
- Participants 55 years of age and older with age-related macular degeneration (AMD) and drusen larger than 63 μm. Vision in the study eye was between 20/20 and 20/400.
- Primary outcome
- Prevention of growth of new blood vessels in the eye (choroidal subretinal neovascularization) in participants with age-related macular degeneration.
- Effect size
- —
- Significance
- Not reported
- Journal
- National Eye Institute (NEI)
- Published
- Nov 29, 2016
Sources
Primary source
- National Eye Institute (NEI) ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.